James Quigley Analyst PerformanceAnalyst at Morgan StanleyJames Quigley is a stock analyst at Morgan Stanley in the medical sector, covering 5 publicly traded companies. Over the past year, James Quigley has issued 7 stock ratings, including buy, hold, and sell recommendations. While full access to James Quigley's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights James Quigley's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings9 Last 6 YearsBuy Recommendations55.56% 5 Buy RatingsCompanies Covered5 Unique Companies Ratings Distribution9RatingsDistribution of strong buy, buy, hold, and sell ratings by James Quigley.RatingPercentageCount Strong Buy0.0%0 ratings Buy55.6%5 ratings Hold33.3%3 ratings Sell11.1%1 ratingsOut of 9 total stock ratings issued by James Quigley at Morgan Stanley, the majority (55.6%) have been Buy recommendations, followed by 33.3% Hold and 11.1% Sell.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ60.0% of companies on NASDAQ3 companiesNYSE40.0% of companies on NYSE2 companiesJames Quigley, an analyst at Morgan Stanley, currently covers 5 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical5 companies100.0%James Quigley of Morgan Stanley specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageLARGE CAP PHARMA3 companies60.0%MED - BIOMED/GENE2 companies40.0% James Quigley's Ratings History at Morgan Stanley Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsNVONovo Nordisk A/S3/2/2026Reiterated Rating$37.50$41.00Neutral$0.0000.00% ROIKYMRKymera Therapeutics2/26/2026Reiterated Rating$95.03$123.00Overweight$0.0000.00% ROINVONovo Nordisk A/S1/22/2026Reiterated Rating$62.30Buy$0.0000.00% ROIKYMRKymera Therapeutics12/9/2025Boost Price Target$94.30$127.00Overweight$0.0000.00% ROINVONovo Nordisk A/S11/28/2025Lower Price Target$48.75$54.00Buy$0.0000.00% ROINVSNovartis9/12/2025Reiterated Rating$127.62$118.00Sell$0.0000.00% ROIKYMRKymera Therapeutics6/3/2025Upgrade$43.13$79.00Overweight$0.0000.00% ROISNYSanofi3/21/2025Initiated Coverage$57.79$65.00Neutral$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
